COMPARISON BETWEEN TWO DIFFERENT CLOPIDOGREL MAINTENANCE DOSES

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。经皮介入治疗后增加氯吡格雷的维持剂量会增加对血小板聚集的抑制。本研究的主要目的是测试氯吡格雷维持剂量从每天75毫克增加到150毫克是否会导致adp诱导的血小板聚集的额外抑制。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Increasing the maintenance dose of clopidogrel following a percutaneous intervention will result in increased suppression of platelet aggregation. The main goal of this study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppresion of ADP-induced platelet aggregation.